NFE2L2 and amyotrophic lateral sclerosis: Dual-pathway compounds, such as hybrid molecules targeting both Nrf2 and NF-κB or Nrf2 and autophagy pathways, are potentially able to fine-tune the neuroinflammatory and proteostatic environment in ALS.